Dr Prasad will lead Enterprise’s development strategy to support the continued advancement of the Company’s respiratory programmes through the clinic

Brighton, UK, 8 February 2022: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced it has appointed Dr Niyati Prasad as Chief Medical Officer. With her extensive experience in respiratory drug development, Dr Prasad will offer full-time, UK-based support to lead the continued advancement of the Company’s clinical programmes.

Enterprise is developing novel disease-modifying therapies which target the underlying mechanisms of mucus congestion, to enhance the clearance of mucus from the airways, restore lung function, and ultimately to reduce morbidity and mortality in chronic respiratory diseases like cystic fibrosis (CF). ETD001, a novel ENaC inhibitor with chemical properties aimed at delivering best-in-class potential, will be evaluated in a CF Phase 2 clinical trial later this year.

Dr Prasad joins Enterprise with over 20 years’ experience at the forefront of global clinical programmes focusing on immunology, respiratory, and rare diseases, having most recently been Senior Director of Clinical Development at GSK. Prior to this she held various leadership roles at leading biopharmaceutical organisations, including Galapagos, Vertex, Takeda and Novartis, where she oversaw drug development teams and programmes for respiratory diseases such as asthma, cystic fibrosis, and chronic obstructive pulmonary disease (COPD), successfully progressing several therapeutics through regulatory approvals.

Dr Prasad received her Medical Degree from Gauhati Medical College, India, and her Diploma in Pharmaceutical Medicine from Universite Libre De Bruxelles. She also completed a Masters in Drug Development Science at Kings College London.

Dr John Ford, CEO, Enterprise Therapeutics, said: “Niyati’s long-standing expertise in respiratory drug development and impressive track record in directing clinical programmes will be an invaluable asset to Enterprise. We are confident that Dr Prasad will play a key role in progressing our novel respiratory therapies through the clinic.”

Dr Niyati Prasad, CMO, Enterprise Therapeutics, commented: “Enterprise is a dynamic and exciting company, with its programmes offering huge potential, especially in the treatment of cystic fibrosis regardless of underlying mutations. I look forward to working closely with the team to bring these novel therapies for respiratory disease to patients.”

For further information about Enterprise’s team, please visit: https://enterprisetherapeutics.com/about-us/leadership-team/.